Huge variations between countries in time for reimbursement decisions on new cancer drugs
Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average ...
Oct 19, 2018